Fig. 3

Brca deficiencies cause differential changes in the tumour microenvironment in response to therapy. A-B Heatmaps presenting the relative abundance of immune cell types in the (A) ID8 Trp53^−/− Brca1^−/− and (B) Trp53^−/− Brca2^−/− tumour microenvironments. Peritoneal washes (n = 5 mice per group) were collected from tumour-bearing mice that had been treated with olaparib, anti-PD-L1 or their combination, and analyzed by flow cytometry 36 h after the last treatment. For each cell type, the value was calculated as the percent of all leukocytes. The percentages were normalized, and each box represents the mean of the 5 biological replicates. C-V. Histograms showing the immune populations that are significantly different from isotype control. The significant changes in cell populations are divided based on genotype: (C-L) for ID8 Trp53^−/− Brca1^−/− and (M-V) for the Trp53^−/− Brca2.^−/− tumour-bearing mice. Each dot represents one biological replicate. Mean values with SEM are shown. ISO = isotype control group and OLA = olaparib treated group. One-way ANOVA with Tukey’s multiple comparison test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001